WRAL Tech Wire

BioDelivery Sciences Names Former GSK Exec as General Counsel

BioDelivery Sciences Moves HQ to Raleigh

Move to larger space made to accommodate more employees, company says.

BioDelivery Sciences Files Application for Acute Pain Treatment

Morrisville-based company seeks FDA approval for ‘breakthrough cancer pain.’ BDSI hopes to launch sales in 2008.

BioDelivery Sciences Receives $30M Payment from Development Partner

BioDelivery Sciences to Pay $7M for Ownership of Drug Delivery technology

RTP-based firm buys all U.S. rights to oral delivery method from QLT USA.

What a Relief: BDSI Lands $60M Deal for Rights to Cancer Pain Reliever

Europe-based Meda pays Morrisville drug development firm $30M up front for North America rights. Meda had already secured European rights.

Application Process for Cancer Drug on Target

BioDelivery Sciences International announced Monday that its June 28 pre-NDA meeting with the U.S. Food and Drug Administration regarding the company’s Phase III BEMA Fentanyl product went according to plan.

BioDelivery Sciences Reports More Positive Test Results on Lead Drug

BioDelivery Sciences Stock Soars 30% on Positive Drug Trial News

Triangle-based drug development firm reports effectiveness in use of breakthrough pain killer.

Drug Firm BDSI Names Marketing Executive

Al Medwar, who once worked for Triangle Pharmaceuticals, joins BDSI from EMD Pharmaceuticals.

FDA Gives OK to Trial for BioDelivery Sciences Drug Delivery Technology

BioDelivery Sciences Can Resume Pain Drug Trial In California

Contract Dispute Breaks Out Between BioDelivery Sciences, One Of Its Investors

Morrisville-based BDSI says Clinical Development Capital sought to acquire rights to drug delivery technology now under trial. CDC seeks to terminate $7M investment.

BioDelivery Sciences Board Member Dies

BioDelivery Sciences Lands European Partner For Pain Drug Delivery System

Morrisville-based pharmaceutical company to receive $2.5 million upfront payment. BDSI also secures rights to delivery system in Europe, U.S. markets.